Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

ESMO Guidelines Committee

doi:10.1016/j.annonc.2022.12.009

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^☆

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

285 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	339-357
Nombre de pages	19
journal	Annals of Oncology
Volume	34
Numéro de publication	4
Les DOIs	https://doi.org/10.1016/j.annonc.2022.12.009
état	Publié - 1 avr. 2023

Accès au document

10.1016/j.annonc.2022.12.009

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{2f416786ecf84ff38a5a78dd49f8f797,

title = "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆",

keywords = "ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), targeted therapy, treatment",

author = "{ESMO Guidelines Committee} and Hendriks, {L. E.} and Kerr, {K. M.} and J. Menis and Mok, {T. S.} and U. Nestle and A. Passaro and S. Peters and D. Planchard and Smit, {E. F.} and Solomon, {B. J.} and G. Veronesi and M. Reck",

note = "Funding Information: UN reports fees paid to her institution as an invited speaker from MSD; fees paid to her institution for advisory board membership and a writing engagement from AstraZeneca; institutional funding as a coordinating PI for Bayer; non-remunerated roles as a PI for clinical trials funded by Deutsche Krebshilfe and as a member of the board of directors and vice-chair of {\textquoteleft}Strahlenschutzkommission{\textquoteright} from the German Commission on Radiological Protection. Funding Information: Manuscript editing support was provided by Richard Lutz, Fraser Simpson, Claire Bramley, Catherine Evans, Jennifer Lamarre and Guy Atchison (ESMO Guidelines staff); this support was funded by ESMO . Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urania Dafni and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino ( ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . Dr Jordi Rem{\'o}n Masip (on behalf of the ESMO Translational Research and Precision Medicine Working Group) and Dr Svetlana Jezdic ( ESMO Medical Affairs Advisor) provided validation support for ESCAT scores. Matt Hellmann provided initial writing support during the conception of this guideline. ",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/j.annonc.2022.12.009",

language = "English",

volume = "34",

pages = "339--357",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "4",

}

TY - JOUR

T1 - Oncogene-addicted metastatic non-small-cell lung cancer

T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

AU - ESMO Guidelines Committee

AU - Hendriks, L. E.

AU - Kerr, K. M.

AU - Menis, J.

AU - Mok, T. S.

AU - Nestle, U.

AU - Passaro, A.

AU - Peters, S.

AU - Planchard, D.

AU - Smit, E. F.

AU - Solomon, B. J.

AU - Veronesi, G.

AU - Reck, M.

N1 - Funding Information: UN reports fees paid to her institution as an invited speaker from MSD; fees paid to her institution for advisory board membership and a writing engagement from AstraZeneca; institutional funding as a coordinating PI for Bayer; non-remunerated roles as a PI for clinical trials funded by Deutsche Krebshilfe and as a member of the board of directors and vice-chair of ‘Strahlenschutzkommission’ from the German Commission on Radiological Protection. Funding Information: Manuscript editing support was provided by Richard Lutz, Fraser Simpson, Claire Bramley, Catherine Evans, Jennifer Lamarre and Guy Atchison (ESMO Guidelines staff); this support was funded by ESMO . Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urania Dafni and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino ( ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . Dr Jordi Remón Masip (on behalf of the ESMO Translational Research and Precision Medicine Working Group) and Dr Svetlana Jezdic ( ESMO Medical Affairs Advisor) provided validation support for ESCAT scores. Matt Hellmann provided initial writing support during the conception of this guideline.

PY - 2023/4/1

Y1 - 2023/4/1

KW - ESCAT

KW - ESMO Clinical Practice Guideline (CPG)

KW - ESMO-MCBS

KW - oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)

KW - targeted therapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85151569857&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.12.009

DO - 10.1016/j.annonc.2022.12.009

M3 - Article

C2 - 36872130

AN - SCOPUS:85151569857

SN - 0923-7534

VL - 34

SP - 339

EP - 357

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -